177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Summary

This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized to either receive personalized or standard PRRT. Personalized PRRT will be determined based on dosimetry calculations after the first cycle. In addition comparisons, will be made with progression-free survival, serial CT imaging, ctDNA, and quality of life questionnaires. Subjects will be followed for 5 years or until they have progression and are switched to another systemic treatment (not including treatment with somatostatin analogues).

Timeline

Start

2023-01-15

Primary completion

2027-12-31

Completion

2031-12-31

Outcome

Outcome not reported

Stopped: “Investigator decision”

Drugs

Indications